|
1
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sia D, Villanueva A, Friedman SL and
Llovet JM: Liver cancer cell of origin, molecular class, and
effects on patient prognosis. Gastroenterology. 152:745–761. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dutta R and Mahato RI: Recent advances in
hepatocellular carcinoma therapy. Pharmacol Ther. 173:106–117.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keating GM: Sorafenib: A review in
hepatocellular carcinoma. Target Oncol. 12:243–253. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finn RS, Zhu AX, Farah W, Almasri J, Zaiem
F, Prokop LJ, Murad MH and Mohammed K: Therapies for advanced stage
hepatocellular carcinoma with macrovascular invasion or metastatic
disease: A systematic review and meta-analysis. Hepatology.
67:422–435. 2017. View Article : Google Scholar
|
|
6
|
Adnane L, Trail PA, Taylor I and Wilhelm
SM: Sorafenib (BAY 43–9006, Nexavar), a dual-action inhibitor that
targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases
VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilhelm S, Carter C, Lynch M, Lowinger T,
Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery
and development of sorafenib: A multikinase inhibitor for treating
cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma
CY, Hua SC, Yang M and Yuan Q: microRNA-1274a, a modulator of
sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9)
down-regulation in hepatocellular carcinoma. Febs Lett.
585:1828–1834. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Potenza N, Mosca N, Zappavigna S,
Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P,
Caraglia M and Russo A: MicroRNA-125a-5p is a downstream effector
of sorafenib in its antiproliferative activity toward human
hepatocellular carcinoma cells. J Cell Physiol. 232:1907–1913.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen J, Jin R, Zhao J, Liu J, Ying H, Yan
H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular,
cellular and microenvironmental mechanism of sorafenib resistance
in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alsaied OA, Sangwan V, Banerjee S, Krosch
TC, Chugh R, Saluja A, Vickers SM and Jensen EH: Sorafenib and
triptolide as combination therapy for hepatocellular carcinoma.
Surgery. 156:270–279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li S, Dai W, Mo W, Li J, Feng J, Wu L, Liu
T, Yu Q, Xu S, Wang W, et al: By inhibiting PFKFB3, aspirin
overcomes sorafenib resistance in hepatocellular carcinoma. Int J
Cancer. 141:2571–2584. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ayati SH, Fazeli B, Momtazi-Borojeni AA,
Cicero A, Pirro M and Sahebkar A: Regulatory effects of berberine
on microRNome in Cancer and other conditions. Crit Rev Oncol
Hematol. 116:147–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tillhon M, Guaman OL, Lombardi P and
Scovassi AI: Berberine: New perspectives for old remedies. Biochem
Pharmacol. 84:1260–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li-Weber M: Targeting apoptosis pathways
in cancer by Chinese medicine. Cancer Lett. 332:304–312. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan W, Li Y, Chen M and Wang Y: Berberine
hydrochloride: Anticancer activity and nanoparticulate delivery
system. Int J Nanomedicine. 6:1773–1777. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ruan H, Zhan YY, Hou J, Xu B, Chen B, Tian
Y, Wu D, Zhao Y, Zhang Y, Chen X, et al: Berberine binds RXRα to
suppress β-catenin signaling in colon cancer cells. Oncogene.
36:6906–6918. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Yang S, Cai X, Dong J, Chen Z,
Wang R, Zhang S, Cao H, Lu D, Jin T, et al: Berberine inhibits EGFR
signaling and enhances the antitumor effects of EGFR inhibitors in
gastric cancer. Oncotarget. 7:76076–76086. 2016.PubMed/NCBI
|
|
19
|
Li M, Zhang M, Zhang ZL, Liu N, Han XY,
Liu QC, Deng WJ and Liao CX: Induction of apoptosis by berberine in
hepatocellular carcinoma HepG2 cells via downregulation of NF-κB.
Oncol Res. 25:233–239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ayati SH, Fazeli B, Momtazi-Borojeni AA,
Cicero A, Pirro M and Sahebkar A: Regulatory effects of berberine
on microRNome in Cancer and other conditions. Crit Rev Oncol
Hematol. 116:147–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang XN, Han X, Xu LN, Yin LH, Xu YW, Qi Y
and Peng JY: Enhancement of apoptosis of human hepatocellular
carcinoma SMMC-7721 cells through synergy of berberine and
evodiamine. Phytomedicine. 15:1062–1668. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Youn MJ, So HS, Cho HJ, Kim HJ, Kim Y, Lee
JH, Sohn JS, Kim YK, Chung SY and Park R: Berberine, a natural
product, combined with cisplatin enhanced apoptosis through a
mitochondria/caspase-mediated pathway in HeLa cells. Biol Pharm
Bull. 31:789–795. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ueshima K, Kudo M, Tanaka M, Kumada T,
Chung H, Hagiwara S, Inoue T, Yada N and Kitai S: Phase I/II study
of sorafenib in combination with hepatic arterial infusion
chemotherapy using low-dose cisplatin and 5-fluorouracil. Liver
Cancer. 4:263–273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blivet-Van EM, Chettouh H, Fartoux L,
Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O and
Desbois-Mouthon C: Epidermal growth factor receptor and HER-3
restrict cell response to sorafenib in hepatocellular carcinoma
cells. J Hepatol. 57:108–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Zhou X, Shen H, Wang D and Wang
Y: Phosphorylated ERK is a potential predictor of sensitivity to
sorafenib when treating hepatocellular carcinoma: Evidence from an
in vitro study. BMC Med. 7:412009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X and Wu XZ: Main antitumor
angiogenesis agents isolated from chinese herbal medicines. Mini
Rev Med Chem. 15:1011–1023. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin M, Bi H, Yan Y, Huang W, Zhang G,
Zhang G, Tang S, Liu Y, Zhang L, Ma J, et al: Parthenolide
suppresses non-small cell lung cancer GLC-82 cells growth via
B-Raf/MAPK/Erk pathway. Oncotarget. 8:23436–23447. 2017.PubMed/NCBI
|
|
29
|
He QL, Minn I, Wang Q, Xu P, Head SA,
Datan E, Yu B, Pomper MG and Liu JO: Targeted delivery and
sustained antitumor activity of triptolide through glucose
conjugation. Angew Chem Int Ed Engl. 55:12035–12039. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun Y, Xun K, Wang Y and Chen X: A
systematic review of the anticancer properties of berberine, a
natural product from Chinese herbs. Anticancer Drugs. 20:757–769.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Su K, Hu P, Wang X, Kuang C, Xiang Q, Yang
F, Xiang J, Zhu S, Wei L and Zhang J: Tumor suppressor berberine
binds VASP to inhibit cell migration in basal-like breast cancer.
Oncotarget. 7:45849–45862. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Q, Qin R, Fang Y and Li H: Berberine
sensitizes human ovarian cancer cells to cisplatin through
miR-93/PTEN/Akt signaling pathway. Cell Physiol Biochem.
36:956–965. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bao J, Huang B, Zou L, Chen S, Zhang C,
Zhang Y, Chen M, Wan JB, Su H, Wang Y and He C: Hormetic effect of
berberine attenuates the anticancer activity of chemotherapeutic
agents. PLoS One. 10:e1392982015. View Article : Google Scholar
|
|
34
|
Hou D, Xu G, Zhang C, Li B, Qin J, Hao X,
Liu Q, Zhang X, Liu J, Wei J, et al: Berberine induces oxidative
DNA damage and impairs homologous recombination repair in ovarian
cancer cells to confer increased sensitivity to PARP inhibition.
Cell Death Dis. 8:e30702017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Das T, Sa G, Saha B and Das K: Multifocal
signal modulation therapy of cancer: Ancient weapon targets. Mol
Cell Biochem. 336:85–95. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu R, Zhang ZQ, Wang B, Jiang HX, Cheng L
and Shen LM: Berberine-induced apoptotic and autophagic death of
HepG2 cells requires AMPK activation. Cancer Cell Int. 14:492014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fu L, Chen W, Guo W, Wang J, Tian Y, Shi
D, Zhang X, Qiu H, Xiao X, Kang T, et al: Berberine Targets
AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and cytochrome-c/caspase
signaling to suppress human cancer cell growth. PLoS One.
8:e692402013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang H, Zhang C, Ning Z, Xu L, Zhu X and
Meng Z: Bufalin enhances anti-angiogenic effect of sorafenib via
AKT/VEGF signaling. Int J Oncol. 48:1229–12241. 2016. View Article : Google Scholar : PubMed/NCBI
|
